MetaVia, Inc. (MTVA)
1.01
-0.06
(-5.61%)
USD |
NASDAQ |
Nov 20, 16:00
1.00
-0.01
(-0.99%)
After-Hours: 20:00
MetaVia Shareholders Equity (Quarterly) : 2.411M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.411M |
| June 30, 2026 | 6.822M |
| March 31, 2026 | 9.073M |
| December 31, 2025 | 5.333M |
| September 30, 2025 | 6.331M |
| June 30, 2025 | 9.624M |
| March 31, 2025 | 4.38M |
| December 31, 2024 | 7.931M |
| September 30, 2024 | 12.95M |
| June 30, 2024 | 18.94M |
| March 31, 2024 | 10.08M |
| December 31, 2023 | 16.68M |
| September 30, 2023 | 21.55M |
| June 30, 2023 | 25.20M |
| March 31, 2023 | 20.51M |
| December 31, 2022 | 21.75M |
| September 30, 2022 | 5.938M |
| June 30, 2022 | 8.833M |
| March 31, 2022 | 11.93M |
| December 31, 2021 | 14.60M |
| September 30, 2021 | 6.125M |
| June 30, 2021 | 9.478M |
| Date | Value |
|---|---|
| March 31, 2021 | 13.15M |
| December 31, 2020 | 7.203M |
| September 30, 2020 | 9.506M |
| June 30, 2020 | 12.34M |
| March 31, 2020 | 7.74M |
| December 31, 2019 | 12.29M |
| September 30, 2019 | -1.025M |
| June 30, 2019 | 1.964M |
| March 31, 2019 | 4.446M |
| December 31, 2018 | 7.774M |
| September 30, 2018 | 10.85M |
| June 30, 2018 | 15.05M |
| March 31, 2018 | 20.82M |
| December 31, 2017 | 3.941M |
| September 30, 2017 | 9.949M |
| June 30, 2017 | 17.73M |
| March 31, 2017 | 25.30M |
| December 31, 2016 | 20.63M |
| September 30, 2016 | 26.99M |
| June 30, 2016 | -7.703M |
| March 31, 2016 | -6.407M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Arrowhead Pharmaceuticals, Inc. | 50.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 9.554M |
| Total Liabilities (Quarterly) | 7.143M |
| Debt to Equity Ratio | 0.0664 |
| Current Ratio | 1.284 |
| Net Debt Paydown Yield | -0.12% |